A DSMB final report determining any drug trial should proceed without changes DOES provide information about efficacy. First, if xanamem showed signs of negative efficacy results, they would not allow the study to proceed. Second, if xanamem showed neutral/no signs of efficacy, they often but not always will not allow the study to proceed and will work with the pharma to terminate the study, especially if their analysis was far into the study with a large data set - so they had a prepoderance of evidence to make that determination. For example Biogen's recent AD phase 3 triall was recently halted for futility - it was judged by a DSMB or third party to have no probably for efficacy. So, dear investors, there is an efficacy judgement when the DSMB continually allows a trial to proceed. So far, so good.
ACW Price at posting:
5.3¢ Sentiment: Buy Disclosure: Held
